ArticleHealth science reports2026
Sublingual Cyclobenzaprine Approval: Expanding Options for Fibromyalgia Management.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Fibromyalgia (FM) is a chronic disorder characterized by widespread pain, fatigue, sleep disturbances, and cognitive issues. It is a multifactorial condition with no single definitive cause, making diagnosis challenging. Current treatments provide only limited relief, leading to significant unmet medical needs. Recently, the US FDA approved sublingual cyclobenzaprine (sCBP) for the treatment of FM, marking the first newly FDA-approved medication for FM in over 15 years. This article aims to explore the current understanding of FM and the pharmacological properties, clinical trials, and potential benefits of sCBP in FM management, as well as the risks associated with its use and future research directions. Methods: We searched for relevant pieces of literature addressing FM management and the development of sublingual cyclobenzaprine. Articles were selected based on their relevance to the study objectives, and the perspective presented in this manuscript was developed through the synthesis of the available evidence and findings reported in these sources. Results: Clinical trials demonstrated that sCBP significantly reduced pain intensity in FM patients in two of the three studies (RELIEF and RESILIENT), with statistically significant mean differences in 11-point numeric rating scale (NRS) scores compared to placebo. sCBP showed a higher peak CBP level with lower norCBP levels, supporting its enhanced pharmacokinetic profile over oral CBP. Common side effects of sCBP included oral discomfort, dry mouth, and abnormal taste, while more serious risks such as serotonin syndrome and arrhythmia were identified. Safety concerns necessitate caution when prescribing sCBP to patients with specific comorbidities or those on other serotonergic medications. Conclusion: The approval of sCBP marks a significant advancement in the treatment of FM, addressing the limitations of current pharmacological options. As the prevalence of FM continues to rise, sCBP offers a promising therapeutic alternative, providing patients with a more effective and rapid treatment option for pain management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.